Bayer Aktiengesellschaft

Bayer Aktiengellschaft

Arndt Brandes

Hilmar Bischoff

Delf Schmidt

Gunter Schmidt

Carsten Schmeck

Klaus-Dieter Bremm

Rolf Angerbauer

Matthias Muller-Gliemann

J&uuml;rgen Stoltefuss

Michael L&ouml;gers

Joachim Schuhmacher

Paul Naab

Holger Paulsen

Jürgen Stoltefuss

Stefan Wohlfeil

Michael Lögers

Henry Giera

Michael Conrad

Jurgen Stoltefuss

Stefan Antons

Stephan Nicholas M&uuml;ller

Michael Lörges

Matthias M&uuml;ller-Gliemann

Hetero-tetrahydroquinolines can be prepared either by condensing correspondingly substituted hetero-tetrahydroquinoline aldehydes with the desired substituent or by reducing the corresponding keto-substituted hetero-tetrahydroquinolines, followed by introduction of the desired substituent by customary methods. The hetero-tetrahydroquinolines are suitable for use as active compounds in medicaments, in particular in medicaments for treating artheriosclerosis and dyslipidaemias.

4-Heteroaryl-tetrahydroquinolines and their use as inhibitors of the cholesterin-ester transfer protein

4-heteroaryl-tetrahydroquinolines and their use as inhibitors of the cholesterin-ester transfer protein

The tetrahydroquinolines can be prepared by condensing appropriately substituted tetrahydroquinoline aldehydes with suitable substances and subsequently varying the substituents present by customary methods. The tetrahydroquinolines are suitable as active compounds in medicaments, in particular in medicaments for the treatment of arteriosclerosis and dyslipidaemias.

4-Phenyltetrahydrochinoline utilized as an inhibitor of the cholesterol ester transfer protein

Substituted tetrahydro-naphthalenes and analogous compounds are prepared by reducing or condensing appropriate functional substituents in substituted tetrahydro-naphthalenes and analogous compounds by customary methods and converting functional groups in this manner into the desired groups. The compounds according to the invention are suitable for use as active compounds in pharmaceuticals, in particular in pharmaceuticals for treating arteriosclerosis and also dyslipidaemias.

Substituted tetrahydronaphthaline and analogous compounds

The tetrahydroquinolines can be prepared by condensing appropriately substituted tetrahydroquinoline aldehydes with suitable substances and subsequently varying the substituents present by customary methods. The tetrahydroquinolines are suitable as active compounds in medicaments, in particular in medicaments. for the treatment of arteriosclerosis and dyslipidaemias.

4-phenyltetrahydrochinoline utilized as an inhibitor of the cholesterol ester transfer protein

Tetrahydroquinolines, processes for their preparation, pharmaceutical compositions containing them, and their use to prevent or treat hyperlipoproteinaemia

The cycloalkano-pyridines are prepared by reacting corresponding cycloalkano-pyridine-aldehydes with suitable organometallic compounds or Wittig or Grignard reagents or reacting compounds of the cycloalkano-pyridine alcohols type with suitable bromine compounds, and optionally varying the functional groups accordingly. The cycloalkanopyridines are suitable as active compounds in medicaments, in particular in medicaments for the treatment of hypertipoproteinaemia and arteriosclerosis.

Cycloalkano-pyridines

The 2-aryl-substituted pyridines are prepared by reacting pyridylaldehydes with organometallic compounds and then selectively reducing the products. The 2-aryl-substituted pyridines are suitable as active compounds in medicaments, in particular in medicaments for the treatment of arteriosclerosis.

2-aryl-substituted pyridines

5-Hydroxyalkyl substituted phenyls and their use in medicaments for the

The cycloalkano-pyridines are prepared by reacting corresponding cycloalkano-pyridine-aldehydes with suitable organometallic compounds or Wittig or Grignard reagents or reacting compounds of the cycloalkano-pyridine alcohols type with suitable bromine compounds, and optionally varying the functional groups accordingly. The, cycloalkanopyridines are suitable as active compounds in medicaments, in particular in medicaments for the treatment of hyperlipoproteinaemia and arteriosclerosis.

Bicyclic-fused pyridines are prepared by introducing the appropriate side chain by reaction of the corresponding aldehydes with the aid of Wittig or Grignard reagents. The bicyclic-fused pyridines are suitable as active compounds in medicaments, in particular in medicaments for the treatment of arteriosclerosi.

Bicyclic-fused pyridines

The heterocyclic-fused pyridines are prepared by reaction of the corresponding heterocyclic-fused pyridine aldehydes with appropriately substituted Grignard or Wittig reagents. The heterocyclic-fused pyridines are suitable as active compounds in medicaments, in particular in medicaments for the treatment of dislipidaemia and arteriosclerosis.

Heterocyclic-fused pyridines

Growing community of inventors

Wuppertal, Germany

Arndt Brandes